Author:
Resta Emanuela,Scioscia Giulia,Lacedonia Donato,Quarato Carla Maria Irene,Panza Francesco,Resta Onofrio,Lepore Giorgia,Buonamico Enrico,Di Lecce Valentina,Carpagnano Giovanna Elisiana,Barbaro Maria Pia Foschino,Rossi Noemi
Abstract
Abstract
Background
The most impacting direct costs associated to COPD for the National Health Systems (NHS) are those related to accesses to the emergency room and hospital admissions, due to the onset of one or more COPD exacerbations. At the same time, severe COPD treatment, that often require a combination of medicaments, represents a substantial economic burden for the National Health Systems (NHS). This study aimed to evaluate the potential saving deriving from the implementation in the prescription of the two currently available single-inhaler triple therapies (SITTs) versus the currently used multiple-inhaler triple therapies (MITTs) in an eligible COPD population residing in the Apulia Region.
Methods
A budget impact model was developed hypothesizing the progressive replacement of the different MITTs on the reference market (Scenario A) with the pre-established SITTs, assuming a degree of penetration of 30%, 50% and 100% (Scenario B). Drug costs were based on prices published on the Official Gazette and therapy durations were based on prescribing information over the year 2019 (IQVIA™ prescription dataset).
Results
Our analysis showed that the extemporaneous MITT with the highest prevalence on the reference market was the inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) combination plus a long-acting muscarinic antagonists (LAMA). This association of medicaments was paradoxically also the one associated to the highest expense value. The expanded use of a pre-established ICS/LAMA/LABA SITT was associated to a significant economic saving, ranging from a minimum of -€ 1,108,814 (SITT use: 30%) to a maximum of -€ 3,658,950 (SITT use: 100%). The cheapest pre-established SITT contained the fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) combination.
Conclusion
A pre-fixed ICS/LAMA/LABA SITT is cost-saving, compared to the different currently used extemporaneous MITTs. Clinicians should consider the potential benefits of finding less expensive regimens while maintaining adequate efficacy in the prescriptive decision making process of COPD patients.
Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. WHO EMRO | Chronic obstructive pulmonary disease (COPD). | Health topics. http://www.emro.who.int/health-topics/chronic-obstructive-pulmonary-disease-copd/index.html. Accessed April 8, 2021.
2. Dal Negro R, Berto P, Tognella SQL. Cost-of-illness of lung disease in the TriVeneto Region, Italy: the GOLD Study. Monaldi Arch Chest Dis. 2002;57(1):3–9. https://pubmed.ncbi.nlm.nih.gov/12174698/.
3. Dal Negro RW, Tognella S, Tosatto R, Dionisi M, Turco P, Donner CF. Costs of chronic obstructive pulmonary disease (COPD) in Italy: The SIRIO study (Social Impact of Respiratory Integrated Outcomes). Respir Med. 2008;102(1):92–101. doi:https://doi.org/10.1016/j.rmed.2007.08.001.
4. Koleva D, Motterlini N, Banfi P, Garattini L. Healthcare costs of COPD in Italian referral centres: A prospective study. Respir Med. 2007;101(11):2312–20. doi:https://doi.org/10.1016/j.rmed.2007.06.020.
5. Blasi F, Cesana G, Conti S, Chiodini V, Aliberti S, Fornari C, Mantovani LG. The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS ONE. 2014;9(6):e101228. doi:https://doi.org/10.1371/journal.pone.0101228.